Skip to main content

Advertisement

SpringerLink
Log in

ZCCHC12, a potential molecular marker of papillary thyroid carcinoma: a preliminary study

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

A gene expression profile analysis using an Affymetrix HG-U133 Plus 2.0 microarray with probes for 38,500 human full-length cDNAs was performed on a primary papillary thyroid carcinoma (PTC) and a nodular goiter (NG). ZCCHC12 was the gene with the most significant differential expression between PTC and NG, and this was verified using fluorescent quantitative PCR (FQ-PCR). A total of 9,485 genes were detected with a difference in transcription levels between PTC and NG. Of these, 2,098 were up-regulated with a signal log ratio (SLR) ≥ 1 and 1,714 were down-regulated with an SLR ≤ −1. Among these up-regulated and down-regulated genes, 12 genes were significantly up-regulated (SLR ≥ 5.0) and 6 genes were significantly down-regulated (SLR ≤ −5.0). The SLR of the ZCCHC12 gene was 8.8. The results of FQ-PCR showed that the medians of the log (ZCCHC12 RNA/GAPDH RNA) in PTC and NG were 0.73 and −1.68, respectively, and the difference between them was significant (P < 0.05). There were no significant correlations between the RNA levels of the ZCCHC12 gene and the clinicopathological and biochemical parameters of PTC in our pilot study. This study showed that a number of differentially expressed genes were discovered between PTC and NG. Significantly, the number of transcript copies of the ZCCHC12 gene in PTC was higher than in NG. The verified results of FQ-PCR were consistent with the microarray screening results. The ZCCHC12 gene may be a novel diagnostic molecular marker of PTC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med. 1996;156:2165–72.

    Article  PubMed  CAS  Google Scholar 

  2. Hegedüs L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24:102–32.

    Article  PubMed  Google Scholar 

  3. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;126:226–31.

    PubMed  CAS  Google Scholar 

  4. Teng W, Shan Zh, Teng X, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med. 2006;354:2783–93.

    Article  PubMed  CAS  Google Scholar 

  5. Wong CKM, Wheeler MH. Thyroid nodules: rational management. World J Surg. 2000;24:934–41.

    Article  PubMed  CAS  Google Scholar 

  6. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:1–24.

    Article  Google Scholar 

  7. Hamberger B, Gharib H, Melton LJ III, et al. Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. Am J Med. 1982;73:381–4.

    Article  PubMed  CAS  Google Scholar 

  8. Coli A, Bigotti G, Zucchetti F, et al. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology. 2002;40:80–7.

    Article  PubMed  CAS  Google Scholar 

  9. Martins L, Matsuo SE, Ebina KN, et al. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab. 2002;87:4806–10.

    Article  PubMed  CAS  Google Scholar 

  10. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.

    Article  PubMed  CAS  Google Scholar 

  11. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393–7.

    Article  PubMed  CAS  Google Scholar 

  12. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454–7.

    PubMed  CAS  Google Scholar 

  13. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625–7.

    Article  PubMed  CAS  Google Scholar 

  14. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001;98:15044–9.

    Article  PubMed  CAS  Google Scholar 

  15. Finley DJ, Zhu B, Barden CB, et al. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg. 2004;240:425–36.

    Article  PubMed  Google Scholar 

  16. Jarzab B, Wiench M, Fujarewicz K, et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 2005;65:1587–97.

    Article  PubMed  CAS  Google Scholar 

  17. DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. World health organization classification of tumors, pathology and genetics of tumors of endocrine organs. Lyon: IARC Press; 2004.

    Google Scholar 

  18. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.

    Article  PubMed  Google Scholar 

  19. Mazzanti C, Zeiger MA, Costouros NG, et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 2004;64:2898–903.

    Article  PubMed  CAS  Google Scholar 

  20. Aldred MA, Huang Y, Liyanarachchi S, et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol. 2004;22:3531–9.

    Article  PubMed  CAS  Google Scholar 

  21. Finley DJ, Arora N, Zhu B, et al. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab. 2004;89:3214–23.

    Article  PubMed  CAS  Google Scholar 

  22. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005;24:6646–56.

    Article  PubMed  CAS  Google Scholar 

  23. Cho G, Lim Y, Zand D, et al. Sizn1 is a novel protein that functions as a transcriptional coactivator of bone morphogenic protein signaling. Mol Cell Biol. 2008;28:1565–72.

    Article  PubMed  CAS  Google Scholar 

  24. Cho G, Bhat SS, Gao J, et al. Evidence that SIZN1 is a candidate X-linked mental retardation gene. Am J Med Genet A. 2008;146A:2644–50.

    Article  PubMed  CAS  Google Scholar 

  25. Cho G, Lim Y, Golden JA. SUMO interaction motifs in Sizn1 are required for promyelocytic leukemia protein nuclear body localization and for transcriptional activation. J Biol Chem. 2009;284:19592–600.

    Article  PubMed  CAS  Google Scholar 

  26. Li H, Liu Q, Hu X, et al. Human ZCCHC12 activates AP-1 and CREB signaling as a transcriptional co-activator. Acta Biochim Biophys Sin (Shanghai). 2009;41:535–44.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Sun Yat-sen University 985 Program Initiation Fund Phase II, the Natural Science Fund of Guangdong Province (sequence number 07001523, 9451008901002400), and the Medical Research Fund of Guangdong Province.

Author information

Authors and Affiliations

  1. State Key Laboratory of Oncology in South China, No. 651 Dongfeng Road East, Guangzhou, 510060, People’s Republic of China

    Qiu-li Li, Fu-jin Chen, Renchun Lai, Zhu-ming Guo, Rongzhen Luo & An-kui Yang

  2. Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, People’s Republic of China

    Qiu-li Li, Fu-jin Chen, Zhu-ming Guo & An-kui Yang

  3. Department of Anesthesiology, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, People’s Republic of China

    Renchun Lai

  4. Department of Pathology, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, 510060, People’s Republic of China

    Rongzhen Luo

Authors
  1. Qiu-li Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fu-jin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Renchun Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhu-ming Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rongzhen Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. An-kui Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to An-kui Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, Ql., Chen, Fj., Lai, R. et al. ZCCHC12, a potential molecular marker of papillary thyroid carcinoma: a preliminary study. Med Oncol 29, 1409–1417 (2012). https://doi.org/10.1007/s12032-011-0018-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0018-6

Keywords

Search

Navigation